Pipeline development activities of Abdominal Aortic Aneurysm
The report provides insights into:
The dynamics of Abdominal Aortic Aneurysm market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rise in the awareness of the disease, and incremental healthcare spending across the world. The current pipeline of Abdominal Aortic Aneurysm is limited as only a few companies are working on Abdominal Aortic Aneurysm.
It provides an opportunity for other companies to enter the market and grab a significant market share. A few companies are also involved in developing Medical devices for the Abdominal Aortic Aneurysm treatment. Key Players such as Merck Serono and AstraZeneca are involved in developing therapies for Abdominal Aortic Aneurysm.
Launch of emerging therapies, such as Metformin Glucophage (Merck Serono) and Ticagrelor (AstraZeneca) is expected to impact the treatment scenario of Abdominal Aortic Aneurysm significantly. Merck Serono is developing Metformin Glucophage tablets which are being evaluated for the treatment of Abdominal Aortic Aneurysm. At present, it is present in phase II/III stage for the evaluation of safety and Efficacy Study of Metformin as add-on Therapy in Non-diabetic Patients With Abdominal Aortic Aneurysm.
AstraZeneca is developing Ticagrelor for Abdominal Aortic Aneurysm treatment. Currently, it is present in Phase II stage for the evaluation of the efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion. Ticagrelor is a platelet aggregation inhibitor. Additionally, several companies, such as Boston Scientific Corporation (TriVascular Stent-Graft System), Bolton Medical (Treovance stent-graft), Cordis Corporation (Cordis Abdominal Aortic Aneurysmstent graft system), TriVascular (TriVascular Ovation Abdominal Stent Graft System) are also developing medical devices for the treatment of Abdominal Aortic Aneurysm.
Scope of the report
Request for sample pages- https://www.delveinsight.com/sample-request/abdominal-aortic-aneurysm-pipeline-insight
The launch of the emerging therapies is expected to significantly impact Abdominal Aortic Aneurysm treatment scenario in the upcoming years:-
Drugs covered1. Metformin Glucophage2. TicagrelorAnd many others
The key players in Abdominal Aortic Aneurysm market are:
1. Merck Serono2. AstraZenecaAnd many others
Table of contents
1. Report Introduction
2. Abdominal Aortic Aneurysm
3. Abdominal Aortic Aneurysm Current Treatment Patterns
4. Abdominal Aortic Aneurysm – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Abdominal Aortic Aneurysm Late Stage Products (Phase-III)
7. Abdominal Aortic Aneurysm Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Abdominal Aortic Aneurysm Discontinued Products
13. Abdominal Aortic Aneurysm Product Profile
14. Abdominal Aortic Aneurysm Key Companies
15. Abdominal Aortic Aneurysm Key Products
16. Dormant and Discontinued Product
17. Abdominal Aortic Aneurysm Unmet Needs
18. Abdominal Aortic Aneurysm Future Perspectives
19. Abdominal Aortic Aneurysm Analyst Review
20. Appendix
21. Report Methodology
The dynamics of Abdominal Aortic Aneurysm market is anticipated tochange in the coming years owing to the improvement in the diagnosismethodologies, rise in the awareness of the disease, and incrementalhealthcare spending across the world. The current pipeline of AbdominalAortic Aneurysm is limited as only a few companies are working on AAA. Itprovides an opportunity for other companies to enter the market and graba significant market share. A few companies are also involved in developingMedical devices for the treatment of AAA.Key Players such as Merck Serono and AstraZeneca are involved indeveloping therapies for AAA. Launch of emerging therapies, such asMetformin Glucophage (Merck Serono) and Ticagrelor (AstraZeneca) isexpected to impact the treatment scenario of AAA significantly.Merck Serono is developing Metformin Glucophage tablets which arebeing evaluated for the treatment of Abdominal Aortic Aneurysm. Atpresent, it is present in phase II/III stage for the evaluation of safety andEfficacy Study of Metformin as add-on Therapy in Non-diabetic PatientsWith Abdominal Aortic Aneurysm.AstraZeneca is developing Ticagrelor for the treatment of AAA. Currently,it is present in Phase II stage for the evaluation of the efficacy of Ticagreloron Abdominal Aortic Aneurysm (AAA) Expansion. Ticagrelor is a plateletaggregation inhibitor.Additionally, several companies, such as Boston Scientific Corporation(TriVascular Stent-Graft System), Bolton Medical (Treovance stent-graft),Cordis Corporation (Cordis AAA stent graft system), TriVascular(TriVascular Ovation Abdominal Stent Graft System) are also developingmedical devices for the treatment of AAA.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/